Document is current
Any future updates will be listed below
-
Authors
Cetiner, Metin https://orcid.org/0000-0002-0918-9204
Finkelberg, Ilja
Schiepek, Felix
Pape, Lars
Hirtz, Raphael
Büscher, Anja K.
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01GM1903E, 01GM2203E)
Universitätsklinikum Essen
- License Information
-
More Information
Article History
Received: 26 February 2024
Accepted: 6 October 2024
First Online: 12 November 2024
Declarations
:
: The study was approved by the local ethics committee (reference number 16-7238-BO). Informed consent was obtained from all participants and/or parents/legal guardians when appropriate. This study was conducted as part of the Network for Early Onset of Cystic Kidney Diseases (NEOCYST) registry in accordance with the Declaration of Helsinki on Biomedical Studies Involving Human Subjects.
: Not required.
: MC is a principal investigator for the RM-IMC-901 study (a Registry of Patients with Biallelic Proopiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1), Leptin Receptor (LEPR) Deficiency Obesity, or Bardet–Biedl Syndrome (BBS), Treated with Setmelanotide) and received payments for lectures, expert testimony and consulting fees and study support from Rhythm Pharmaceuticals. MC also received payments for lectures from Canon Medical Systems. LP received payments for lectures and expert testimony from Rhythm Pharmaceuticals. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
